Efficacy of propafenone in paramyotonia congenita.
Alfonsi
E
E
Clinical Neurophysiology Unit, Fondazione Istituto Neurologico C. Mondino IRCCS, Via Mondino, 2, 27100 Pavia, Italy. enrico.alfonsi@mondino.it
Merlo
I M
IM
Tonini
M
M
Ravaglia
S
S
Brugnoni
R
R
Gozzini
A
A
Moglia
A
A
D000200:Action Potentials / Q000187:drug effects / Q000235:genetics; D000328:Adult; D000889:Anti-Arrhythmia Agents / Q000008:administration & dosage; D004252:DNA Mutational Analysis; D004334:Drug Administration Schedule; D005819:Genetic Markers / Q000235:genetics; D005820:Genetic Testing; D006801:Humans; D008297:Male; D009122:Muscle Hypertonia / Q000188:drug therapy / Q000235:genetics / Q000503:physiopathology; D018482:Muscle, Skeletal / Q000187:drug effects* / Q000378:metabolism / Q000503:physiopathology; D009154:Mutation / Q000235:genetics; D020967:Myotonic Disorders / Q000188:drug therapy* / Q000235:genetics / Q000503:physiopathology; D062553:NAV1.4 Voltage-Gated Sodium Channel; D010243:Paralysis / Q000188:drug therapy / Q000235:genetics / Q000503:physiopathology; D011405:Propafenone / Q000008:administration & dosage*; D026941:Sodium Channel Blockers / Q000008:administration & dosage*; D015222:Sodium Channels / Q000187:drug effects* / Q000235:genetics / Q000378:metabolism; D016896:Treatment Outcome
D000889:Anti-Arrhythmia Agents; D005819:Genetic Markers; D062553:NAV1.4 Voltage-Gated Sodium Channel; C106251:SCN4A protein, human; D026941:Sodium Channel Blockers; D015222:Sodium Channels; D011405:Propafenone